View Post

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: AWARE-1 trial demonstrates pelareorep primes an adaptive immune response Systemic delivery yields robust pelareorep replication selectively in tumor cells Pelareorep administration increases CelTIL – known to be associated with positive clinical outcomes Peripheral T cell clonality emerges as potential predictive and prognostic biomarker Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, …